StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

TG Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 82.4%. For fiscal 2025 it was 83.7%, against 88.3% the year before. The highest annual figure on record is 94.0% in fiscal 2023.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202583.7%−4.6
FY2024Dec 31, 202488.3%−5.7
FY2023Dec 31, 202394.0%+3.5
FY2022Dec 31, 202290.5%+2.3
FY2021Dec 31, 202188.2%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202682.9%−3.7
Q1 FY2026Mar 31, 202683.6%−3.5
Q4 FY2025Dec 31, 202580.2%−5.6
Q3 FY2025Sep 30, 202582.6%−6.2
Q2 FY2025Jun 30, 202586.6%−2.1
Q1 FY2025Mar 31, 202587.1%−4.3
Q4 FY2024Dec 31, 202485.8%+3.6
Q3 FY2024Sep 30, 202488.9%−9.0
Q2 FY2024Jun 30, 202488.7%+0.6
Q1 FY2024Mar 31, 202491.4%+2.4
Q4 FY2023Dec 31, 202382.1%−14.1
Q3 FY2023Sep 30, 202397.9%+0.0
Q2 FY2023Jun 30, 202388.1%+5.6
Q1 FY2023Mar 31, 202389.0%–
Q4 FY2022Dec 31, 202296.3%–
Q3 FY2022Sep 30, 202297.9%–
Q1 FY2021Mar 31, 202182.5%–

More TG Therapeutics figures

See a number that looks wrong?